Argenta, Antabio Achieve Milestone in Anti-bacterial Drug Discovery Collaboration
News Mar 10, 2014
The attainment of the milestone triggers the drawdown of a further €1.7 million tranche of their Seeding Drug Discovery Award.
A novel lead series of pan-metallo beta-lactamase inhibitors has been identified that, in combination with carbapenems, restores antibacterial activity against life-threatening clinical isolates whilst exhibiting no toxicity or developmental issues. Multi-drug resistant Gram-negative bacteria account for most hospital infections worldwide, causing up to 75,000 deaths yearly and extra healthcare costs/productivity losses of >€1.5 billion. One of the most effective treatments is the use of carbapenem antibiotics; however, the usefulness of these antibiotics is becoming increasingly compromised due to the rise of clinical resistance, associated with the spread of genes encoding various MBL enzymes, primarily the carbapenemases of the NDM, VIM and IMP types.
The Argenta/Antabio collaboration began in February 2013, when the Wellcome Trust awarded Antabio €4.7 Million to fund the discovery of a novel, safe and efficacious pan-inhibitor of bacterial metallo beta-lactamases (MBLs). Since then, Argenta has provided medicinal chemistry, computer-aided drug design and ADME/PK services, together with its integrated drug discovery expertise, to assist Antabio achieve its research goals.
“To have achieved on schedule our first milestone in our collaboration with the Trust is a great satisfaction for our team, and a sign that solid foundations are in place for this discovery programme.” said Marc Lemonnier, CEO of Antabio. “We believe the therapeutic potential of a small-molecule pan-MBL inhibitor is very significant and will eventually improve the outcome for patients suffering from severe nosocomial Gram-negative infections. This milestone will support further lead optimization efforts to progress our compounds rapidly towards pre-clinical candidate nomination.”
John Montana, Argenta’s Managing Director, added “We are delighted to have achieved this milestone with our collaboration partner, Antabio, and look forward to our continuing partnership on this exciting drug discovery project. Once again, this achievement underlines Argenta’s ability to deliver high quality science within exacting deadlines.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018